Zepbound Maintenance Dose: What the Label Says After You Reach Your Goal

There is no separate Zepbound maintenance dose after goal weight. The FDA label's maintenance doses are 5, 10, or 15 mg once weekly for weight, and 10 or 15 mg for sleep apnea. The label sets no different dose for after you reach your goal [1].

In SURMOUNT-4, stopping tirzepatide led to regain, while staying on it kept weight off [2]. In SURMOUNT-MAINTAIN, a 5 mg step-down kept off more weight than placebo but less than staying on 10 or 15 mg [3]. Stomach side effects came mostly while the dose was rising [3]; see our page on Zepbound side effects.

In this guide you will learn:

• Which Zepbound doses are maintenance doses, and which are only steps
• What the label says about the Zepbound maintenance dose after goal weight
• What stopping did in SURMOUNT-4
• What a 5 mg step-down did in SURMOUNT-MAINTAIN
• How eating and strength training fit in

This page gives no personal dosing advice; your prescriber decides your dose.

Table of Contents

• What is the Zepbound maintenance dose?
• Is there a different Zepbound dose after you reach your goal weight?
• What happens if you stop Zepbound at your goal weight?
• Can you step down to Zepbound 5 mg for maintenance? What SURMOUNT-MAINTAIN found
• How your prescriber may choose your Zepbound maintenance dose
• Other Zepbound maintenance options: less often, lower than 5 mg, or switching to Foundayo
• Eating and strength training to hold your weight on a maintenance dose
• Frequently asked questions
• Key takeaways

What Is the Zepbound Maintenance Dose?

The Zepbound maintenance dose is 5 mg, 10 mg, or 15 mg injected once weekly for weight reduction and long-term maintenance, according to the FDA label. For obstructive sleep apnea, it is 10 mg or 15 mg, and 15 mg is the maximum for all uses [1].

Everyone starts at 2.5 mg once weekly for 4 weeks. The label states that "the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage" [1]. After 4 weeks it goes up to 5 mg, and it may then rise in 2.5 mg steps, at least 4 weeks apart [1].

Why are 7.5 and 12.5 mg only steps? Trial doses rose to a final 5, 10, or 15 mg. Lilly's medical information page (reviewed November 2024) says "Lilly did not study Zepbound 7.5 and 12.5 mg as maintenance dosages" [4].

In SURMOUNT-1, people on 5, 10, and 15 mg lost 15.0%, 19.5%, and 20.9% of their body weight at 72 weeks, compared with 3.1% on placebo [1]. For the full schedule, see our page on the tirzepatide dosage chart.

Is There a Different Zepbound Dose After You Reach Your Goal Weight?

No. The Zepbound maintenance dose after goal weight is the same 5, 10, or 15 mg. The indication already covers keeping weight off: Zepbound is approved to "reduce excess body weight and maintain weight reduction long term" [1]. The label sets no separate dose, schedule, or stopping rule for reaching a goal.

What the label gives your prescriber is a rule for choosing: "Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage" [1]. Some ranking pages get this wrong.

The Medication Guide says to "use ZEPBOUND exactly as your healthcare provider tells you to" [5]. Never change your dose or schedule on your own.

What Happens If You Stop Zepbound at Your Goal Weight?

In SURMOUNT-4, people who stopped Zepbound (tirzepatide) after 36 weeks regained 14.0% of their body weight over the next year, while those who stayed on it lost another 5.5% [1][2]. Regain was common but varied.

Everyone first took open-label tirzepatide for 36 weeks, raised to 10 or 15 mg, and lost 20.9% on average. The trial then randomly assigned 670 people to stay on tirzepatide or switch to placebo for 52 weeks [1]. Of those, 71% were women, and Lilly funded the trial [2].

• Most kept their loss on tirzepatide. 89.5% of those who stayed on it kept at least 80% of their earlier loss, compared with 16.6% on placebo [2].
• The gap from the start. Over all 88 weeks, weight fell 25.3% on tirzepatide and 9.9% on placebo [2].

Health Markers After Regain

A 2026 post hoc analysis looked at 308 people on placebo who had lost at least 10% by week 36 [6]. By our count from its groups, 254 of them (82%) regained at least a quarter of their loss. Waist size, systolic blood pressure, and HbA1c rose in step with regain.

Waist size went up 0.8 cm in the lowest regain group and 14.7 cm in the highest. Systolic blood pressure rose even with little regain: by 6.8 mm Hg in people who regained less than a quarter (post hoc, Lilly-sponsored) [6].

One health-system record study followed 7,938 people who stopped semaglutide or tirzepatide within 3 to 12 months. Weight change after stopping varied widely between people, and 19.6% restarted the same drug within a year [7]. They had stopped early and lost less than trial participants. For the earlier months, see our page on how long it takes for Zepbound to start working.

Can You Step Down to Zepbound 5 mg for Maintenance? What SURMOUNT-MAINTAIN Found

In SURMOUNT-MAINTAIN, the one randomized step-down trial we found, lowering Zepbound (tirzepatide) to 5 mg kept off more weight than placebo but less than staying on 10 or 15 mg [3].

Everyone first took tirzepatide for 60 weeks, raised to their maximum tolerated dose (MTD) of 10 or 15 mg. At week 60, the trial randomly assigned 378 people in a 3:3:2 ratio to stay on their MTD, drop to 5 mg, or switch to placebo for 52 weeks [3]. The design paper planned no dose changes during that year [8]. From week 84, anyone who regained more than half of their loss could get rescue tirzepatide [3].

In Lilly's own analysis (a different method from the Lancet's), average weight over the maintenance year went from 89.0 to 94.6 kg on 5 mg and 89.5 to 88.7 kg on MTD [10]. Lilly's maintenance-year rates for MTD and 5 mg vs placebo: diarrhea 7.2% and 4.9% vs 1.1%, vomiting 6.5% and 0.7% vs 0%, and nausea 5.8% and 4.2% vs 2.2%. Stopping for adverse events: 0%, 0.7%, and 0% [10].

What the Trial Cannot Tell You

• Who ran it. Lilly funded the trial, and 7 of its 13 authors are Lilly employees [3].
• 5 mg vs staying. The design paper says the trial is "not specifically powered to directly compare the two strategies" [8].
• Who took part. The trial randomized only people who tolerated 10 or 15 mg and lost at least 5% [8].
• Scope. One maintenance year, US sites only, no people with type 2 diabetes, and 65% women among the 441 enrolled [3][8].
• Reporting. The registry and the paper word the primary endpoint differently, and we read only the abstract [3][9].

The authors wrote that 5 mg "might provide a valuable alternative to discontinuation, although individuals' treatment response might vary" [3].

How Your Prescriber May Choose Your Zepbound Maintenance Dose

Your prescriber picks your Zepbound maintenance dose after goal weight from two factors in the label: how well it works for you and how well you tolerate it [1]. These questions can help at your next visit:

• Which dose, and why? Ask whether staying, stepping down, or another plan fits your results and side effects.
• How will we track it? Agree on how often to check weight, waist, and appetite.
• What if my weight creeps up? Ask what the plan is. If you take birth control pills, the label advises a non-oral method or an added barrier method for 4 weeks after each dose escalation; by that wording, moving back up to a higher dose counts too [1].
• What about side effects? The label allows a lower maintenance dose if one is not tolerated [1].
• What will coverage and cost look like? Plans set their own renewal rules; see our page on what insurance covers Zepbound. Self-pay prices differ by dose; see our page on the Zepbound coupon.
• What if I plan a pregnancy? The label says to stop Zepbound when a pregnancy is recognized, and it lists a pregnancy registry at 1-844-524-0039 [1].

Other Zepbound Maintenance Options: Less Often, Lower Than 5 mg, or Switching to Foundayo

The Zepbound label doses once weekly only, and 5 mg is the lowest approved maintenance dose [1]. Label rule for a missed dose: take it within 4 days (96 hours), or skip it and keep your usual day [1].

• Less often than weekly. We found no published randomized trial of tirzepatide given less often than weekly, and none comparing a taper with stopping at once (PubMed and ClinicalTrials.gov, September 2026). A small pilot trial registered in September 2026 has not started recruiting.
• Below 5 mg. Doses under 5 mg are not approved for maintenance [1]. Our page on microdosing tirzepatide covers what is known.
• Switching to Foundayo. Foundayo (orforglipron) is a once-daily oral GLP-1 medicine whose label also covers maintaining weight reduction long term [11]. In ATTAIN-MAINTAIN, people who switched from tirzepatide to Foundayo and had reached a weight plateau kept 74.7% of their weight reduction at 52 weeks, compared with 49.2% on placebo [12]. No group stayed on Zepbound, so the trial does not compare the two. See our page on Foundayo vs Zepbound.

Do not combine them: the label says Zepbound is not recommended with other tirzepatide products or with any GLP-1 medicine [1].

Eating and Strength Training to Hold Your Weight on a Maintenance Dose

In three of the label's weight trials, including SURMOUNT-1 and SURMOUNT-4, every Zepbound dose came with a diet of about 500 kcal a day below needs and counseling on at least 150 minutes of activity a week [1]. A 2025 joint nutrition advisory adds resistance training and enough protein to help protect muscle and bone [13].

The advisory suggests strength training at least 3 times a week plus at least 150 minutes of moderate aerobic exercise, fitted to your fitness level [13]. It also notes that SURMOUNT-4 offered diet and exercise counseling during treatment, yet most people regained notable weight after stopping without continued nutrition support [13].

General habits (not label instructions):

• Put a protein food at every meal, and eat it first when you feel full fast.
• Keep a meal structure if appetite returns, for example after a step-down: set meal times and planned snacks instead of grazing.

For protein targets and their caveats, see how much protein to eat on a GLP-1. Our GLP-1 workout at home shows a simple strength routine, and our GLP-1 meal plan lays out a week of meals. For protein-focused recipes and meal ideas for the maintenance phase, see our guide.

The advisory also lists nutrition for keeping weight off after stopping a GLP-1 as a research gap [13].

Frequently Asked Questions

Why are 7.5 mg and 12.5 mg not Zepbound maintenance doses?

They are escalation steps. The label lists only 5, 10, and 15 mg as maintenance doses for weight, and Lilly did not study 7.5 or 12.5 mg as maintenance doses. So 7.5 mg Zepbound is not a maintenance dose under the label.

Can you stay on 2.5 mg of Zepbound for maintenance?

The label says 2.5 mg is for starting treatment and is not approved as a maintenance dose. Ask your prescriber before any change.

What is the lowest maintenance dose of Zepbound?

5 mg once weekly for weight. For sleep apnea, it is 10 mg once weekly.

Can I stop taking Zepbound once I reach my goal weight?

Talk with your prescriber first. In SURMOUNT-4, people who switched to placebo regained 14.0% of their body weight within a year, on average. Regain varied from person to person.

Do you have to taper off Zepbound?

The label has no taper schedule, and we found no published randomized trial comparing a taper with stopping at once. How to stop is your prescriber's decision.

Can I take Zepbound every other week for maintenance?

The label doses Zepbound once weekly. We found no published randomized trial of tirzepatide given every other week. See our page on microdosing tirzepatide.

Is the Mounjaro maintenance dose the same as Zepbound's?

Not exactly. Mounjaro is a type 2 diabetes medicine that starts at 2.5 mg and rises in 2.5 mg steps if more blood sugar control is needed, up to 15 mg in adults [14]. Its label does not use the word maintenance. See our Zepbound vs Mounjaro comparison.

How long do you stay on a Zepbound maintenance dose?

The label's indication is long term and sets no end date. The two maintenance trials followed people for 88 and 112 weeks.

Key Takeaways

• Label doses. 5, 10, or 15 mg once weekly for weight; 10 or 15 mg for sleep apnea. 2.5, 7.5, and 12.5 mg are not maintenance doses.
• No separate goal dose. The Zepbound maintenance dose after goal weight uses the same doses, chosen on response and tolerability.
• Stopping. In SURMOUNT-4, people who stopped regained 14.0% of body weight within a year, on average.
• Stepping down. In SURMOUNT-MAINTAIN, 5 mg kept off more than placebo but less than staying on 10 or 15 mg.
• Safety. Change your dose only with your prescriber, and stop Zepbound when a pregnancy is recognized.

References

1. Zepbound (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly
2. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024
3. Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet, 2026
4. Why is Zepbound (tirzepatide) 7.5 and 12.5 mg doses not included as maintenance or therapeutic doses, last reviewed November 21, 2024: Lilly Medical
5. Zepbound Medication Guide, revised 08/2026: Eli Lilly
6. Horn DB et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial. JAMA Intern Med, 2026
7. Gasoyan H et al. Obesity treatments and weight changes in clinical practice after discontinuation of semaglutide or tirzepatide. Diabetes Obes Metab, 2026
8. Horn DB et al. Tirzepatide for the maintenance of body weight reduction: rationale, design, and baseline characteristics of SURMOUNT-MAINTAIN. Obesity, 2025
9. SURMOUNT-MAINTAIN study record NCT06047548: ClinicalTrials.gov
10. Lilly news release on SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN results, May 12, 2026: Eli Lilly
11. Foundayo (orforglipron) Prescribing Information, revised 07/2026: U.S. Food and Drug Administration
12. Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med, 2026
13. Nutritional priorities to support GLP-1 therapy for obesity: joint advisory from ACLM, ASN, OMA, and TOS, 2025
14. Mounjaro (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly

This article is for education only and is not medical advice. It summarizes the FDA label and published research, and it gives no personalized dosing advice. Talk to your prescriber about your treatment and your dose. Read our full medical disclaimer.